Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric Crohn's disease
NL-OMON53427Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of mirikizumab in Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Clinical remission at Week 52 for platform exploratory analysis, Endoscopic response at Week 52 for platform exploratory analysis and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON53427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53427.